Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria
Pancreatic Cancer|Advanced Pancreatic Carcinoma
DRUG: all approved chemotherapeutic agents from second line
Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy, 24 months
To identify prognostic and predictive features for treatment efficacy, 24 months|To identify prognostic and predictive features for clinical outcome, 24 months|To identify prognostic and predictive features for Neuropathy, Relative frequency of Grade 3 and Grade 4 Adverse Events according to the Common Terminology Criteria of Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Febrile Neuropathy, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Thrombocytopenia, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Anemia, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Nausea/Vomiting, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Skin toxicity, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for rash, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for mucositis, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Fatigue, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for Allergic reactions, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To identify prognostic and predictive features for all other Adverse Events, Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented, 24 months|To investigate the effect of dose density on treatment efficacy of first- and second line therapy, 24 months|To investigate the effect of dose modifications on treatment efficacy of first- and second line therapy, 24 months|To perform a comparative effectiveness analysis of different palliative second line chemotherapy regimens, 24 months|To evaluate treatment behaviours after progression on palliative second line therapy, 24 months|To analyse efficacy of palliative third line therapy, 24 months|To analyse patterns of BRCA testing in real-world practice, 24 months|To analyse the impact of BRCA testing in real-world practice on treatment decisions, 24 months|To analyse the impact of BRCA testing in real-world practice on outcome, 24 months|Prevalence of primary tumor resection in patients with metastatic or locally advanced inoperable pancreatic cancer, 24 months|Prevalence of metastasectomy in patients with metastatic or locally advanced inoperable pancreatic cancer, 24 months|To evaluate the impact of primary tumor resection on outcome, 24 months|To evaluate the impact of metastasectomy on outcome, 24 months|To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on dose density of FOLFIRINOX, 24 months|To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on rate of febrile neutropenia, 24 months|To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on overall outcome, 24 months|To evaluate patterns of molecular profiling in the real world treatment practice of advanced pancreatic cancer, 24 months|To evaluate patterns of next generation sequencing (NGS) in the real world treatment practice of advanced pancreatic cancer, 24 months|To analyse treatment patterns and outcome in the subgroup of very young (<40 years old) patients with advanced pancreatic cancer, 24 months|To analyse treatment patterns and outcome in the subgroup of very old (>75 years old) patients with advanced pancreatic cancer, 24 months|To investigate the impact of diabetes mellitus on treatment efficacy of palliative chemotherapy and disease outcome, 24 months|To investigate the impact of antidiabetic therapy on treatment efficacy of palliative chemotherapy and disease outcome, 24 months|To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome, 24 months
1000 adult patients with locally advanced inoperable and/or metastasized PDAC undergoing first line chemotherapy